About this briefing
Medtech innovation briefings summarise the published evidence and information available for individual medical technologies. The briefings provide information to aid local decision-making by clinicians, managers and procurement professionals.
Medtech innovation briefings aim to present information and critically review the strengths and weaknesses of the relevant evidence, but contain no recommendations and are not formal NICE guidance.
This briefing was developed for NICE by Birmingham & Brunel External Assessment Centre. The interim process and methods statement sets out the process NICE uses to select topics, and how the briefings are developed, quality-assured and approved for publication.
Birmingham and Brunel External Assessment Centre
Medical Technologies Evaluation Programme, NICE
Dr Catherine Meads, Reader in Health Technology Assessment, Brunel University
Dr Carole Cummins, University of Birmingham
The following specialist commentators provided comments on a draft of this briefing:
Dr Magdi El‑Omar, Consultant Interventional Cardiologist, lead for the acute chest pain service and divisional lead for infection prevention and control, Manchester Heart Centre, Manchester Royal Infirmary
Professor Anthony Gershlick, Consultant Cardiologist, University Hospitals of Leicester NHS Trust and Honorary Professor of Interventional Cardiology, University of Leicester
Dr Stephen Hoole, Consultant Interventional Cardiologist and Interventional Research Lead, Papworth Hospital NHS Foundation Trust and Honorary Fellow, University of Cambridge
Dr Magdi El‑Omar received an honorarium approximately 3 years ago from Atrium (before they were taken over by Maquet) for a presentation on INFUSE‑AMI at the EuroPCR conference in Paris.
No other relevant interests were declared.
© National Institute for Health and Care Excellence, 2016. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.